Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Farnesyl transferase inhibitor resistance probed by target mutagenesis.

Blood - 15 Sept 2007

Raz Tal, Nardi Valentina, Azam Mohammad, Cortes Jorge, Daley George Q

Abstract excerpt

Mutation in the target oncoprotein is a common mechanism of resistance to tyrosine kinase inhibitors, as exemplified by the many BCR/ABL mutations that thwart imatinib activity in patients with chronic myelogenous leukemia. It remains unclear whether normal cellular protein targets of chemotherapeutics will evolve drug resistance via mutation to a similar extent. We conducted an in vitro screen for resistance to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Farnesyltranstransferase
Share to Imatinib Mesylate

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Piperazines

Share to Piperidines

Share to Protein Prenylation

Share to Pyridines

Source

Open in PubMed Open full text

Identifiers

PMID: 17536018
DOI: 10.1182/blood-2006-12-064907
PMCID: PMC1976354

Genes

BCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Farnesyl transferase inhibitor resistance probed by target mutagenesis.PMID 17536018Read ↗

Overriding imatinib resistance with a novel ABL kinase inhibitor.Semantic proximity Read ↗

Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutantsSemantic proximity Read ↗

Designing Effective Protein Lysine and Arginine Methyltransferase Inhibitors for Chemotherapeutic TargetingSemantic proximity Read ↗

An in vitro screening to identify drug-resistant mutations for target-directed chemotherapeutic agents.Semantic proximity Read ↗

Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinibSemantic proximity Read ↗

Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras?Semantic proximity Read ↗

Evolving therapies: farnesyltransferase inhibitors.Semantic proximity Read ↗

Mutation in Abl kinase with altered drug-binding kinetics indicates a novel mechanism of imatinib resistance.Semantic proximity Read ↗

Farnesylated proteins as anticancer drug targets: from laboratory to the clinic.Semantic proximity Read ↗

Resistance in the land of molecular cancer therapeutics.Semantic proximity Read ↗

Dual functional genomics reveals a broad and convergent landscape of asciminib resistance in BCR::ABL1.Semantic proximity Read ↗

LIN28A-Dependent Kinome and Phosphoproteome Reprogramming Promotes Imatinib ResistanceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.